Nowadays, novel biomarkers to guide treatment allocation beyond PD-L1 expression are under investigation, such as circulating tumor DNA (ctDNA), which showed a promising activity in predicting disease recurrence [8], or multiomics algorithms, combining tumor-intrinsic, immune microenvironment, and systemic factors, supporting the development of precision immunotherapy strategies [17]. Here, CD274 is linked to neoplasm.